Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination
Novartis announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali® (ribociclib) plus endocrine therapy extended PFS compared to endocrine therapy alone, regardless of the presence of visceral metastases in pre-, peri- and postmenopausal women. December 08, 2018